STEMLINE THERAPEUTICS INC's ticker is STML and the CUSIP is 85858C107. A total of 61 filers reported holding STEMLINE THERAPEUTICS INC in Q1 2014. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $3,288,000 | -75.0% | 679,533 | -45.2% | 0.00% | 0.0% |
| Q4 2019 | $13,176,000 | +110.1% | 1,239,578 | +105.8% | 0.00% | 0.0% |
| Q3 2019 | $6,271,000 | -18.2% | 602,441 | +20.4% | 0.00% | -50.0% |
| Q2 2019 | $7,663,000 | +35.0% | 500,214 | +13.2% | 0.00% | +100.0% |
| Q1 2019 | $5,676,000 | -4.0% | 441,768 | -29.1% | 0.00% | 0.0% |
| Q4 2018 | $5,912,000 | +26.8% | 622,654 | +121.6% | 0.00% | 0.0% |
| Q3 2018 | $4,664,000 | +8.1% | 281,003 | +4.5% | 0.00% | 0.0% |
| Q2 2018 | $4,314,000 | +21.4% | 268,786 | +15.7% | 0.00% | 0.0% |
| Q1 2018 | $3,554,000 | +22.5% | 232,314 | +24.9% | 0.00% | 0.0% |
| Q4 2017 | $2,902,000 | +51.9% | 186,034 | +8.0% | 0.00% | 0.0% |
| Q3 2017 | $1,911,000 | +24.2% | 172,201 | +2.9% | 0.00% | 0.0% |
| Q2 2017 | $1,539,000 | +12.6% | 167,373 | +4.7% | 0.00% | 0.0% |
| Q1 2017 | $1,367,000 | -3.8% | 159,920 | +20.3% | 0.00% | 0.0% |
| Q4 2016 | $1,421,000 | +15.3% | 132,891 | +16.8% | 0.00% | 0.0% |
| Q3 2016 | $1,232,000 | +61.7% | 113,770 | +1.0% | 0.00% | – |
| Q2 2016 | $762,000 | +47.7% | 112,699 | +1.6% | 0.00% | – |
| Q1 2016 | $516,000 | -22.1% | 110,909 | +5.6% | 0.00% | – |
| Q4 2015 | $662,000 | -28.5% | 105,066 | +0.1% | 0.00% | -100.0% |
| Q3 2015 | $926,000 | -16.6% | 104,950 | +11.2% | 0.00% | 0.0% |
| Q2 2015 | $1,110,000 | -15.4% | 94,363 | +4.0% | 0.00% | 0.0% |
| Q1 2015 | $1,312,000 | +25.7% | 90,704 | +48.1% | 0.00% | 0.0% |
| Q4 2014 | $1,044,000 | +48.5% | 61,229 | +8.4% | 0.00% | – |
| Q3 2014 | $703,000 | -12.9% | 56,481 | +2.6% | 0.00% | -100.0% |
| Q2 2014 | $807,000 | -26.2% | 55,063 | +2.5% | 0.00% | 0.0% |
| Q1 2014 | $1,093,000 | +7.3% | 53,701 | +3.2% | 0.00% | 0.0% |
| Q4 2013 | $1,019,000 | -62.4% | 52,038 | -13.0% | 0.00% | -50.0% |
| Q3 2013 | $2,711,000 | +244.9% | 59,848 | +81.5% | 0.00% | +100.0% |
| Q2 2013 | $786,000 | – | 32,981 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lyon Street Capital, LLC | 762,941 | $7,248,000 | 7.29% |
| NEXTHERA CAPITAL LP | 711,558 | $6,760,000 | 2.79% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 585,930 | $4,366,000 | 2.71% |
| Consonance Capital Management LP | 1,155,793 | $10,980,000 | 0.81% |
| Pier Capital, LLC | 423,667 | $4,025,000 | 0.80% |
| KNOTT DAVID M | 155,795 | $1,480,000 | 0.70% |
| Eventide Asset Management | 1,086,400 | $10,321,000 | 0.46% |
| Empire Life Investments Inc. | 373,863 | $3,552,000 | 0.32% |
| Telemetry Investments, L.L.C. | 41,588 | $395,000 | 0.25% |
| Polar Capital LLP | 2,302,666 | $21,875,000 | 0.23% |